Adolor's MOR antagonist meets constipation endpoint

Adolor Corp. (NASDAQ:ADLR) said ADL5945 met the primary endpoint of the weekly average number of spontaneous bowel movements vs. placebo in two similar Phase II trials to treat opioid-induced constipation (OIC). The news sent shares of Adolor up more than 15% early Wednesday. The stock finished the day off $0.10 to $2.11. ...